Clinical Trials
206 trialsNivolumab and Ipilimumab in People With Aggressive Pituitary Tumors
Memorial Sloan Kettering Cancer Center
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Crinetics Pharmaceuticals Inc.
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
University of Washington
ArTisaN
Imperial College London
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men
Premier Research
RESCUE
Sparrow Pharmaceuticals
BEVANEC
Hospices Civils de Lyon
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
Academic and Community Cancer Research United
Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
Ohio State University Comprehensive Cancer Center
Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
METALLICA
MedSIR
TALENT
Grupo Espanol de Tumores Neuroendocrinos
68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours
Azienda USL Reggio Emilia - IRCCS
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Stanford University
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
M.D. Anderson Cancer Center
NIPINEC
Intergroupe Francophone de Cancerologie Thoracique
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
National Cancer Institute (NCI)
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma
Peking University
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Dana-Farber Cancer Institute
Study of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception
Premier Research
A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)
Clarity Pharmaceuticals Ltd
Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors
Latin American Cooperative Oncology Group
Cabozantinib and Nivolumab for Carcinoid Tumors
Dana-Farber Cancer Institute
Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
Alliance for Clinical Trials in Oncology
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
Grupo Espanol de Tumores Neuroendocrinos
DUNE
Grupo Espanol de Tumores Neuroendocrinos
Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver
Abramson Cancer Center at Penn Medicine
NET02
The Christie NHS Foundation Trust
NET-002
Sunnybrook Health Sciences Centre
Phase 2 Study of ONC201 in Neuroendocrine Tumors
Case Comprehensive Cancer Center
SNIPP
University Health Network, Toronto
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
EVACEL
Federation Francophone de Cancerologie Digestive
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
Academic and Community Cancer Research United
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
Olivia Newton-John Cancer Research Institute
The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma
Peking Union Medical College Hospital
HORMONET
AC Camargo Cancer Center
Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer
Fujian Medical University
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Dana-Farber Cancer Institute
AcSé
UNICANCER
Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
Mayo Clinic
Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
National Cancer Institute (NCI)
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Stanford University
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Roswell Park Cancer Institute
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
SCRI Development Innovations, LLC